Synthesis and Physicochemical Characterization of the Process-Related Impurities of Olmesartan Medoxomil. Do 5-(Biphenyl-2-yl)-1-triphenylmethyltetrazole Intermediates in Sartan Syntheses Exist?

During the process development for multigram-scale synthesis of olmesartan medoxomil (OM), two principal regioisomeric process-related impurities were observed along with the final active pharmaceutical ingredient (API). The impurities were identified as N-1- and N-2-(5-methyl-2-oxo-1,3-dioxolen-4-y...

Full description

Bibliographic Details
Main Authors: Iwona Dams, Anna Ostaszewska, Maria Puchalska, Justyna Chmiel, Piotr Cmoch, Iwona Bujak, Agata Białońska, Wojciech J. Szczepek
Format: Article
Language:English
Published: MDPI AG 2015-12-01
Series:Molecules
Subjects:
Online Access:http://www.mdpi.com/1420-3049/20/12/19762
id doaj-597524469ce24822a97c25c3abeac4a0
record_format Article
spelling doaj-597524469ce24822a97c25c3abeac4a02020-11-24T22:56:06ZengMDPI AGMolecules1420-30492015-12-012012213462136310.3390/molecules201219762molecules201219762Synthesis and Physicochemical Characterization of the Process-Related Impurities of Olmesartan Medoxomil. Do 5-(Biphenyl-2-yl)-1-triphenylmethyltetrazole Intermediates in Sartan Syntheses Exist?Iwona Dams0Anna Ostaszewska1Maria Puchalska2Justyna Chmiel3Piotr Cmoch4Iwona Bujak5Agata Białońska6Wojciech J. Szczepek7Pharmaceutical Research Institute, Rydygiera 8, Warsaw 01-793, PolandPharmaceutical Research Institute, Rydygiera 8, Warsaw 01-793, PolandPharmaceutical Research Institute, Rydygiera 8, Warsaw 01-793, PolandPharmaceutical Research Institute, Rydygiera 8, Warsaw 01-793, PolandPharmaceutical Research Institute, Rydygiera 8, Warsaw 01-793, PolandPharmaceutical Research Institute, Rydygiera 8, Warsaw 01-793, PolandFaculty of Chemistry, University of Wrocław, Joliot-Curie 14, 50-383 Wrocław, PolandPharmaceutical Research Institute, Rydygiera 8, Warsaw 01-793, PolandDuring the process development for multigram-scale synthesis of olmesartan medoxomil (OM), two principal regioisomeric process-related impurities were observed along with the final active pharmaceutical ingredient (API). The impurities were identified as N-1- and N-2-(5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl derivatives of OM. Both compounds, of which N-2 isomer of olmesartan dimedoxomil is a novel impurity of OM, were synthesized and fully characterized by differential scanning calorimetry (DSC), infrared spectroscopy (IR), nuclear magnetic resonance spectroscopy (NMR) and high-resolution mass spectrometry/electrospray ionization (HRMS/ESI). Their 1H, 13C and 15N nuclear magnetic resonance signals were fully assigned. The molecular structures of N-triphenylmethylolmesartan ethyl (N-tritylolmesartan ethyl) and N-tritylolmesartan medoxomil, the key intermediates in OM synthesis, were solved and refined using single-crystal X-ray diffraction (SCXRD). The SCXRD study revealed that N-tritylated intermediates of OM exist exclusively as one of the two possible regioisomers. In molecular structures of these regioisomers, the trityl substituent is attached to the N-2 nitrogen atom of the tetrazole ring, and not to the N-1 nitrogen, as has been widely reported up to the present. This finding indicates that the reported structural formula of N-tritylolmesartan ethyl and N-tritylolmesartan medoxomil, as well as their systematic chemical names, must be revised. The careful analysis of literature spectroscopic data for other sartan intermediates and their analogs with 5-(biphenyl-2-yl)tetrazole moiety showed that they also exist exclusively as N-2-trityl regioisomers.http://www.mdpi.com/1420-3049/20/12/19762crystal structureimpuritiesmedoxomilNMR spectroscopyolmesartanprodrugsregioisomerssartansstructuresynthesis
collection DOAJ
language English
format Article
sources DOAJ
author Iwona Dams
Anna Ostaszewska
Maria Puchalska
Justyna Chmiel
Piotr Cmoch
Iwona Bujak
Agata Białońska
Wojciech J. Szczepek
spellingShingle Iwona Dams
Anna Ostaszewska
Maria Puchalska
Justyna Chmiel
Piotr Cmoch
Iwona Bujak
Agata Białońska
Wojciech J. Szczepek
Synthesis and Physicochemical Characterization of the Process-Related Impurities of Olmesartan Medoxomil. Do 5-(Biphenyl-2-yl)-1-triphenylmethyltetrazole Intermediates in Sartan Syntheses Exist?
Molecules
crystal structure
impurities
medoxomil
NMR spectroscopy
olmesartan
prodrugs
regioisomers
sartans
structure
synthesis
author_facet Iwona Dams
Anna Ostaszewska
Maria Puchalska
Justyna Chmiel
Piotr Cmoch
Iwona Bujak
Agata Białońska
Wojciech J. Szczepek
author_sort Iwona Dams
title Synthesis and Physicochemical Characterization of the Process-Related Impurities of Olmesartan Medoxomil. Do 5-(Biphenyl-2-yl)-1-triphenylmethyltetrazole Intermediates in Sartan Syntheses Exist?
title_short Synthesis and Physicochemical Characterization of the Process-Related Impurities of Olmesartan Medoxomil. Do 5-(Biphenyl-2-yl)-1-triphenylmethyltetrazole Intermediates in Sartan Syntheses Exist?
title_full Synthesis and Physicochemical Characterization of the Process-Related Impurities of Olmesartan Medoxomil. Do 5-(Biphenyl-2-yl)-1-triphenylmethyltetrazole Intermediates in Sartan Syntheses Exist?
title_fullStr Synthesis and Physicochemical Characterization of the Process-Related Impurities of Olmesartan Medoxomil. Do 5-(Biphenyl-2-yl)-1-triphenylmethyltetrazole Intermediates in Sartan Syntheses Exist?
title_full_unstemmed Synthesis and Physicochemical Characterization of the Process-Related Impurities of Olmesartan Medoxomil. Do 5-(Biphenyl-2-yl)-1-triphenylmethyltetrazole Intermediates in Sartan Syntheses Exist?
title_sort synthesis and physicochemical characterization of the process-related impurities of olmesartan medoxomil. do 5-(biphenyl-2-yl)-1-triphenylmethyltetrazole intermediates in sartan syntheses exist?
publisher MDPI AG
series Molecules
issn 1420-3049
publishDate 2015-12-01
description During the process development for multigram-scale synthesis of olmesartan medoxomil (OM), two principal regioisomeric process-related impurities were observed along with the final active pharmaceutical ingredient (API). The impurities were identified as N-1- and N-2-(5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl derivatives of OM. Both compounds, of which N-2 isomer of olmesartan dimedoxomil is a novel impurity of OM, were synthesized and fully characterized by differential scanning calorimetry (DSC), infrared spectroscopy (IR), nuclear magnetic resonance spectroscopy (NMR) and high-resolution mass spectrometry/electrospray ionization (HRMS/ESI). Their 1H, 13C and 15N nuclear magnetic resonance signals were fully assigned. The molecular structures of N-triphenylmethylolmesartan ethyl (N-tritylolmesartan ethyl) and N-tritylolmesartan medoxomil, the key intermediates in OM synthesis, were solved and refined using single-crystal X-ray diffraction (SCXRD). The SCXRD study revealed that N-tritylated intermediates of OM exist exclusively as one of the two possible regioisomers. In molecular structures of these regioisomers, the trityl substituent is attached to the N-2 nitrogen atom of the tetrazole ring, and not to the N-1 nitrogen, as has been widely reported up to the present. This finding indicates that the reported structural formula of N-tritylolmesartan ethyl and N-tritylolmesartan medoxomil, as well as their systematic chemical names, must be revised. The careful analysis of literature spectroscopic data for other sartan intermediates and their analogs with 5-(biphenyl-2-yl)tetrazole moiety showed that they also exist exclusively as N-2-trityl regioisomers.
topic crystal structure
impurities
medoxomil
NMR spectroscopy
olmesartan
prodrugs
regioisomers
sartans
structure
synthesis
url http://www.mdpi.com/1420-3049/20/12/19762
work_keys_str_mv AT iwonadams synthesisandphysicochemicalcharacterizationoftheprocessrelatedimpuritiesofolmesartanmedoxomildo5biphenyl2yl1triphenylmethyltetrazoleintermediatesinsartansynthesesexist
AT annaostaszewska synthesisandphysicochemicalcharacterizationoftheprocessrelatedimpuritiesofolmesartanmedoxomildo5biphenyl2yl1triphenylmethyltetrazoleintermediatesinsartansynthesesexist
AT mariapuchalska synthesisandphysicochemicalcharacterizationoftheprocessrelatedimpuritiesofolmesartanmedoxomildo5biphenyl2yl1triphenylmethyltetrazoleintermediatesinsartansynthesesexist
AT justynachmiel synthesisandphysicochemicalcharacterizationoftheprocessrelatedimpuritiesofolmesartanmedoxomildo5biphenyl2yl1triphenylmethyltetrazoleintermediatesinsartansynthesesexist
AT piotrcmoch synthesisandphysicochemicalcharacterizationoftheprocessrelatedimpuritiesofolmesartanmedoxomildo5biphenyl2yl1triphenylmethyltetrazoleintermediatesinsartansynthesesexist
AT iwonabujak synthesisandphysicochemicalcharacterizationoftheprocessrelatedimpuritiesofolmesartanmedoxomildo5biphenyl2yl1triphenylmethyltetrazoleintermediatesinsartansynthesesexist
AT agatabiałonska synthesisandphysicochemicalcharacterizationoftheprocessrelatedimpuritiesofolmesartanmedoxomildo5biphenyl2yl1triphenylmethyltetrazoleintermediatesinsartansynthesesexist
AT wojciechjszczepek synthesisandphysicochemicalcharacterizationoftheprocessrelatedimpuritiesofolmesartanmedoxomildo5biphenyl2yl1triphenylmethyltetrazoleintermediatesinsartansynthesesexist
_version_ 1725654935505207296